Collaborations, Alliances and License Agreements
- Spero Therapeutics in its collaboration with Pfizer Inc to develop and commercialize SPR206, an IV-administered gram negative antibiotic product candidate outside of the US, Greater China, South Korea, and certain Southeast Asian countries
- Spero Therapeutics in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop Spero’s orally administered SPR720 for the treatment of tuberculosis
- Synlogic in its $80M equity investment at a premium from Ginkgo Bioworks and entry into a long-term strategic platform collaboration
- Aura Biosciences in its license agreement with Clearside Biomedical for suprachoroidal delivery of AU-011
- DNAtrix in its collaboration with Valo Therapeutics to develop “armed” oncolytic vaccines for cancer therapy using DNAtrix’s clinical stage oncolytic viruses
- Spero Therapeutics in its collaboration with Everest Medicines to develop and commercialize SPR206 , an IV-administered gram negative antibiotic product candidate in Greater China, South Korea, and certain Southeast Asian countries
- Synlogic in its global R&D collaboration with AbbVie to develop novel synthetic medicines to treat inflammatory bowel disease
- Spero Therapeutics in its license with Meiji Pharmaceuticals, its acquisition of worldwide rights to VXc-486/VXc-100 antibacterial compounds from Vertex Pharmaceuticals, and its acquisition of next generation antibacterial candidates from Pro Bono Bio Ltd
- Macrolide Pharmaceuticals in its agreement with Cempra to develop a synthetic manufacturing process for solithromycin
- Biogen Idec in its collaboration with Ataxion to develop drugs to treat hereditary ataxias
- Amorsa Therapeutics in its research, option and license agreement with Janssen Pharmaceuticals, to develop novel ketamine-derived drugs for treatment-resistant depression
- Paratek Pharmaceuticals in its $485M global collaboration with Novartis
- Numerous foundational in-licenses from leading universities, hospitals and institutions, including Harvard, MIT, Boston University, Case Western, Michigan, Einstein College, MGH, Tufts, University of Florida, others
Venture Capital Financings
- CAM Capital in its investments in Primmune and Arcellx
- Santi Therapeutics, Avilar Therapeutics, Athenen Therapeutics, Arcuate Therapeutics and Nayan Therapeutics, recently launched companies incubated by RA Capital, in each of their inaugural financings from RA Capital affiliates
- Aura Biosciences in its $30M and $40M financings to advance the clinical development of its Ocular Melanoma treatment
- Sofinnova Ventures, Ysios Capital, INKEF Capital and Sectoral Asset Management in $30M and $50M investments in Ranier Therapeutics (formerly BioClin Therapeutics)
- Spero Therapeutics in its $51.7M financing to advance its pipeline of antibacterials focused on drug-resistant bacterial infections
- Synlogic in its $42M, $40M, $30M and $42M financings to develop “living therapeutics”
- Macrolide Pharmaceuticals in its $22M Series A financing to develop novel antibiotics
- Opsonix in its $8M Series A financing to develop a broad spectrum pathogen-extracting therapy
- Venture investors in the $21 Series B financing of Aura Biosciences, to treat ocular melanoma
- RA Capital in numerous venture financings, including Ventus Therapeutics, Quench Bio, Arvinas, Cidara Therapeutics, G1 Therapeutics and White Swell Medical
- MVM Life Science Partners in numerous venture financings, including AccuVein, BioTheranostics, Zipline Medical, Cheetah Medical and Solx
- Merck Research and Licensing (MRL) Ventures in several financings, including RaNA Therapeutics and miRagen Therapeutics
M&A and Public Offerings
- Amorsa Therapeutics in its acquisition by an undisclosed publicly traded CNS biopharma company on undisclosed terms
- Spero Therapeutics in its $88M Initial Public Offering, $75M follow-on public offering and $10M Registered Direct Offering
- Synlogic in its IPO by way of a reverse merger with Mirna Therapeutics, Inc.
- Synlogic in its $50M follow-on public offering
- AFT Pharmaceuticals in its $33M Initial Public Offering
- Beacon Endoscopic in its sale to Covidien
Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.
Mintz represented Synlogic in an $80 million financing from Ginkgo Bioworks and the parties' related collaboration to expand development of Synlogic’s Synthetic Biotic medicines. Mintz previously helped Synlogic raise over $200 million in capital, plus another $40 million through a reverse merger.
After helping Spero raise over $200 million, Mintz represented the biopharmaceutical company in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb).
Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.
In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.
Mintz represents Urgent Care Centers of New England, Inc. and CareWell Urgent Care Centers of MA. Mintz helped CareWell set up its first licensed urgent care center in Massachusetts and helped CareWell, UCCONE, and a third party establish a joint venture to own several CareWell urgent care centers.
Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.